Compare stocks

Idorsia Ltd is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company focuses on the discovery, development, and commercialization of innovative medicines. Idorsia’s pipeline includes treatments for a variety of conditions, with a particular emphasis on central nervous system disorders, cardiovascular diseases, and rare diseases. Notably, it was founded in June 2017 as a spinoff from Actelion, following its acquisition by Johnson & Johnson. Idorsia leverages its deep scientific expertise to progress its drug candidates from early-stage research through clinical development, aiming to address significant unmet medical needs. Sources: - Company Website - Publicly available financial and corporate reports

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.